ClinicalTrials.gg
Not yet recruitingNCT07461675Updated Mar 10, 2026

Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection

A Phase 3 interventional study of Atezolizumab in Hepato Cellular Carcinoma (HCC) and Immunotherapy, sponsored by University of Geneva, Switzerland. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by University of Geneva, Switzerland · Phase 3, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing atezolizumab in Carcinoma, Hepatocellular — 17 open to participants now, 29 under way, 7 of them phase 3. atezolizumab · Carcinoma, Hepatocellular.

Planned enrollment
24th of 41
30 · median 40
Started
2026
with 5 others
Phase 3
11 of 41
2 open now
Primary completion
2029-06
later than 25 of 28 live
Registered
33rd of 41
by date

Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, this one is the 24th largest by planned enrollment, is one of 6 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 25 of the 28 other live ones, and was the 33rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 41 studies testing atezolizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing atezolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

Our study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor.

HCC is the most prevalent primary liver cancer, responsible for nearly 800,000 deaths annually, making it the third leading cause of cancer-related mortality worldwide. Ablation by radiologic micro-waves or surgical resection represent at the moment the only curative therapies for early stages of the disease. Despite these curative options, HCC recurrence is frequent.

Recently, immunotherapy has demonstrated good results on patient overall survival for advanced stages of HCC in comparison to sorafenib. Because of the beneficial effect of immunotherapy on HCC, several groups have attempt to use it as adjuvant therapy in order to reduce the recurrence rate. However the results are at the moment controversial. One can hypothetize that postoperative inflammation and liver regeneration can negatively impact the effect of the immunotherapy. Therefore, the administration of the treatmeent before surgical resection could overcome this issue.

03

Conditions studied

  • Hepato Cellular Carcinoma (HCC)
  • Immunotherapy

Keywords

  • Neoadjuvant treatment
  • Hepatocellular carcinoma
  • atezolizumab
  • hepatectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult patients undergoing liver resection for HCC at the Geneva University Hospitals (HUG), with prior informed and signed consent.
  • Patients of childbearing age must be willing to use a at the day of inclusion and for at least 5 months after the last infusion.
  • Negative pregnancy test at inclusion
  • Patients will require to be eligible for surgical resection according to the BCLC guidelines (very early to early stage with preserved liver function and good patient condition) (4).
  • The control group will include data from the patients in our ongoing research project (study protocol 2023-02372), undergoing liver resection without prior ICI therapy (n = 30).

Exclusion criteria

Exclusion Criteria:

  • Patients who do not ultimately undergo liver resection due to unforeseen reasons (this happens rarely, such as in the presence of unexpected HCC progression discovered during surgery).
  • Patients with an ongoing pregnancy (an unlikely event, as non-surgical HCC treatments would be prioritized in such cases).
  • Patients unable to follow procedures due to language barriers, insufficient comprehension of project language, or unable to give consent.
  • Patients \<18 years.
  • Patients with medical history of allergy or severe AEs to ICI therapy
  • Pregnant and/or breastfeeding women. Lactating women should stop lactation or will be excluded from the study as breastfeeding under atezolizumab is not recommended. Furthermore, breastfeeding is not recommended for at least 5 months after the last dose.
  • patients and patients with haematological disorder leading to a deficient immunity
  • Patients with hepatic and/or cardiovascular deficiencies that contra-indicate surgery. Compensated cirrhotic patients are expected and will be included in the study as no dosage modification of the atezolizumab is required for these patients.
  • Patients who received a live or attenuated vaccine in the last 28 days before inclusion in the study.
  • Patients with untreated and/or C or . HIV patients under treatment with normal can be included. Hepatitis B and/or C patients under antiviral therapies can be included.
  • Patients with history of inflammatory pneumopathy, active and patients treated with a systemic immunotherapy in the last 6 months.
  • Patients under treatment during the inclusion will be excluded.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treated group. Patients receiving immunotherapy before surgical resection of their HCC

    Drug: Atezolizumab

  • No intervention
    Control group

    Patients undergoing surgical resection for HCC without any neoadjuvant treatment

Interventions

  • Patients will receive two doses of atzolizumab 6 and 3 weeks before surgery

06

What researchers measure

Primary outcomes

  1. Difference in frequency of flow cytometry-assessed HCC-specific CD8+ cells in the periphery (PBMC) between patients with vs without ICI therapy prior to liver surgery

    We will assess the impact of ICI therapy on the frequency of HCC-specific CD8+ lymphocytes. The currently recruited patients will be compared to historical patients without ICI treatment. After flow cytometry sorting, bulk RNA sequencing of CD8+ cells will be performed. The SEQTR method will define the frequency of HCC-specific TCR.

    Time frame: Four years

Secondary outcomes

  1. Tumor microenvironment changes induced by ICI therapy

    Especially changes in HCC-specific T cell response in the periphery after versus prior to surgery. TCR subtypes will be identified by TCR single cell sequencing in the peripheral blood and in the tumor. Additionnaly immune cell type population, their activation and suppression markers as well as the frequency of the subtypes will be assesed by flow cytometry (CD8, CD4, memory T cells, exhausted markers (PD-L1, TIM-3, LAG-2)).

    Time frame: four years

  2. Overall survival and recurrence free survival

    We will analyze the survival and recurrence rates in order to evaluate the impact or potential benefit of neoadjuvant atezolizumab

    Time frame: four years

  3. Tumor burden

    We will evaluate the impact of atezolizumab on the tumor burden such as the number and size of HCC nodules and compare it before the treatment and before surgery to evaluate the level of downstaging of the tumor that we can expect.

    Time frame: Four years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jun 2029, 38 months later.

Of 86 non-industry phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 109. This study's planned 38 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 10, 2026
StartEst.
Mar 25, 2026
Primary completionEst.
Jun 1, 2029
CompletionEst.
Dec 31, 2029
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07461675
Lead sponsor
University of Geneva, Switzerland
Responsible party
Christian Toso (Professor, University of Geneva, Switzerland) — Principal investigator
First posted
Mar 10, 2026
Start date
Mar 25, 2026 (estimated)
Primary completion
Jun 1, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 10, 2026

Study contacts

Charles-Henri Wassmer, MD-PhD
Contact
charles-henri.wassmer@hug.ch
+41786682206
Christian Toso, Professor
Contact
christian.toso@hug.ch
+41795533673

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atezolizumab

Start the discussion